Phaseline

Companies › AiViva BioPharma

AiViva BioPharma: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Ophthalmology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AIV007
VEGF inhibitor
–Phase 2Neovascular (Wet) Age-Related Macular Degeneration; Neovascular Age-related Macular DegenerationJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05698329AIV007Phase 1Neovascular Age-related Macular DegenerationOphthalmologyMar 2025
NCT07557121AIV007Phase 2Neovascular (Wet) Age-Related Macular DegenerationOphthalmologyJun 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

EyeBiotech Adverum Biotechnologies EyePoint Pharmaceuticals SpyGlass Pharma Alcon Research

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.